General Electric is selling its biopharma business to Danaher Corp. for $21.4b. The deal complements Danaher’s current biologics workflow solutions. GE’s biopharma business includes process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and related services. GE has shrunk considerably since the financial crisis a decade ago and is seeking to divest even more of …

Large pharmaceutical and diagnostic players companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, some with limited revenue. In March 2019, Thermo Fisher Scientific agreed to pay $1.7b to acquire Brammer Bio, which offers pre-clinical and analytical development, process optimization, and analytical qualification services, as well as clinical and commercial drug substances, …

Catalent, Inc., a $2.46b provider of delivery technologies for drugs, biologics, and consumer and animal health products, is buying Paragon Bioservices, Inc., a developer of viral vectors for gene therapies. The deal Complements Catalent’s biologics business. Paragon engages in the production and purification of therapeutic proteins, monoclonal antibodies, viral vectors, and vaccines-VLPs, as well as production of master and working …

Smith & Nephew plc (LSE:SN, NYSE:SNN), a $4.9b maker of orthopedic, wound management, sports medicine and trauma & extremities products, is acquiring Osiris Therapeutics, Inc., a provider of regenerative medicine products, including skin, bone graft and articular cartilage substitutes. The deal accelerates S&N’s wound management business. Osiris’ products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, …

Medtronic plc (NYSE: MDT), a $29.95b manufacturer of cardio-vascular, orthopedic, spinal and other medical devices., is buying EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics), a maker of a catheter-based, temperature-controlled cardiac ablation systems. The acquisition expands Medtronic’s cardiac ablation portfolio. EPIX manufactures a duct-based temperature system for controlling cardiac ablation for arrhythmia (arrhythmia), including atrial fibrillation. Its DiamondTemp ablation system, …

Abbott Laboratories, a $20.4b global developer of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals is buying Cephea Valve Technologies, Inc, a developer of a less-invasive heart valve replacement technology for mitral valve disease. The deal Strengthens Abbott’s in structural heart therapies. Cephea’s artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of …

Bristol-Myers Squibb Company, a $20.8b global biopharma company is buying Celgene Corporation, a $13b developer of therapies for cancer and inflammatory diseases. The Deal strengthens Bristol-Myers in oncology, cardiovascular disease, immunology and inflammation. Celgene is known for its blockbuster Thalomid and Revlimid cancer drugs. The combined company will have nine products with more than $1b in annual sales. In addition to the approved …

GlaxoSmithKline plc (GSK), a large European-based pharmaceutical manufacturer is acquiring TESARO Inc., an oncology-focused biopharmaceutical company. The transaction accelerates GSK’s commercial capability in oncology. TESARO’s major marketed product is Zejula (niraparib), an oral, once-daily ribose polymerase (PARP) inhibitor approved for use in ovarian cancer. It works by blocking an enzyme that cancer cells use to repair damage in their DNA. In Q3 2018, …

Colfax Corporation, a $3.6b diversified maker of fluid handling and other engineered products is acquiring DJO Global Inc, a leading maker of orthopedic bracing and other non-invasive rehab devcies. The deal diversifies CFX’ revenue streams and end-market exposure, reduces cyclicality, weights healthcare and creates a new growth platform for CFX. DJO’s primary offerings are: Aircast, DonJoy, and ProCare. It partners with …

Medtronic Plc (NYSE:MDT), agreed to buy Mazor Robotics Ltd. (NASDAQ:MZOR), a maker of robotic guidance systems, for $1.64bto strengthen its position in spine surgery. Medtronic’s spine division had been hit off-stride after the problems encountered with Kyphon purchase in 2007. Sales force flux, off-label use of a controversial biologics product, a DOJ investigation and nimble competitors chipping away have challenged …